Envestnet Asset Management Inc. Has $6.67 Million Position in Henry Schein, Inc. $HSIC

Envestnet Asset Management Inc. lifted its holdings in Henry Schein, Inc. (NASDAQ:HSIC) by 103.1% in the 2nd quarter, Holdings Channel.com reports. The firm owned 91,299 shares of the company’s stock after buying an additional 46,357 shares during the quarter. Envestnet Asset Management Inc.’s holdings in Henry Schein were worth $6,669,000 as of its most recent SEC filing.

A number of other large investors have also bought and sold shares of the business. Vanguard Personalized Indexing Management LLC lifted its stake in Henry Schein by 3.5% in the second quarter. Vanguard Personalized Indexing Management LLC now owns 4,669 shares of the company’s stock valued at $341,000 after buying an additional 157 shares in the last quarter. Equitable Trust Co. increased its position in shares of Henry Schein by 3.1% during the second quarter. Equitable Trust Co. now owns 5,317 shares of the company’s stock worth $388,000 after acquiring an additional 158 shares in the last quarter. TD Asset Management Inc raised its holdings in shares of Henry Schein by 0.8% during the second quarter. TD Asset Management Inc now owns 22,016 shares of the company’s stock worth $1,608,000 after acquiring an additional 164 shares during the period. Radnor Capital Management LLC lifted its position in Henry Schein by 1.6% in the 2nd quarter. Radnor Capital Management LLC now owns 11,415 shares of the company’s stock valued at $834,000 after acquiring an additional 180 shares in the last quarter. Finally, V Square Quantitative Management LLC boosted its stake in Henry Schein by 6.3% in the 2nd quarter. V Square Quantitative Management LLC now owns 3,377 shares of the company’s stock worth $247,000 after purchasing an additional 200 shares during the period. 96.62% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

Several analysts have issued reports on HSIC shares. JPMorgan Chase & Co. lifted their price target on Henry Schein from $76.00 to $78.00 and gave the company an “overweight” rating in a research note on Wednesday, November 5th. Wall Street Zen upgraded Henry Schein from a “hold” rating to a “buy” rating in a report on Saturday. Barrington Research set a $79.00 target price on Henry Schein and gave the company an “outperform” rating in a research note on Wednesday, November 5th. UBS Group decreased their price target on shares of Henry Schein from $75.00 to $70.00 and set a “neutral” rating for the company in a research note on Wednesday, August 6th. Finally, Weiss Ratings reiterated a “hold (c-)” rating on shares of Henry Schein in a report on Friday, October 31st. Five analysts have rated the stock with a Buy rating, eight have given a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, Henry Schein currently has an average rating of “Hold” and a consensus price target of $76.08.

Henry Schein Stock Performance

Shares of NASDAQ HSIC opened at $73.22 on Wednesday. The company has a debt-to-equity ratio of 0.51, a quick ratio of 0.78 and a current ratio of 1.41. The stock has a 50 day moving average price of $66.46 and a 200 day moving average price of $68.86. The stock has a market capitalization of $8.62 billion, a PE ratio of 23.62, a price-to-earnings-growth ratio of 2.06 and a beta of 0.84. Henry Schein, Inc. has a 52 week low of $60.56 and a 52 week high of $82.49.

Henry Schein (NASDAQ:HSIC) last posted its quarterly earnings results on Tuesday, November 4th. The company reported $1.38 earnings per share for the quarter, topping the consensus estimate of $1.27 by $0.11. The firm had revenue of $3.34 billion for the quarter, compared to analyst estimates of $3.28 billion. Henry Schein had a return on equity of 14.36% and a net margin of 3.05%. Henry Schein has set its FY 2025 guidance at 4.880-4.960 EPS. Analysts predict that Henry Schein, Inc. will post 4.74 earnings per share for the current fiscal year.

Henry Schein Company Profile

Henry Schein, Inc provides health care products and services to dental practitioners, laboratories, physician practices, and ambulatory surgery centers, government, institutional health care clinics, and other alternate care clinics worldwide. It operates through two segments, Health Care Distribution, and Technology and Value-Added Services.